Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 12/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6881767 | 0.90 | DRD4 (0.45) | DRD4HTTDRD2KDM4EALDH1A1 | |
| SCHEMBL6095517 | 0.86 | KCNH2 (0.48) | DRD4HTTPDE10AKDM4EALDH1A1 | |
| SCHEMBL6093816 | 0.86 | KCNH2 (0.48) | DRD4HTTPDE10AKDM4EALDH1A1 | |
| SCHEMBL6882898 | 0.83 | DRD4 (0.48) | DRD4HTTPDE10ADRD2KDM4E | |
| SCHEMBL13559752 | 0.80 | KCNH2 (0.52) | KCNH2 | |
| SCHEMBL6880423 | 0.79 | DRD4 (0.54) | DRD4HTTDRD2KDM4EALDH1A1 | |
| SCHEMBL6881772 | 0.78 | DRD4 (0.48) | DRD4HTTDRD2KDM4EALDH1A1 | |
| SCHEMBL6881688 | 0.77 | LMNA (0.52) | DRD4HTTPDE10ADRD2KDM4E | |
| SCHEMBL6097411 | 0.76 | HTT (0.46) | DRD4HTTKDM4EALDH1A1CYP3A4 | |
| SCHEMBL6880280 | 0.76 | HPGD (0.67) | DRD4HTTDRD2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040166137-A1 | Hetero-substituted benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2004-08-26 | — | — | US | disclosed |
| WO-2004043913-A2 | HETERO-SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND ANTIVIRAL USES THEREOF | TRIMERIS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040166137-A1 | Hetero-substituted benzimidazole compounds and antiviral uses thereof | MAVS, TIMM13, TIMM10 | DRD4 1550/4885HTT 1686/4885PDE10A 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.